If you're currently receiving testosterone through a telehealth platform — no in-person visit, no physical exam, prescription managed entirely through video calls and messaging — December 31, 2026 is a date you need on your calendar. It's the day the regulatory framework that made your entire prescribing relationship possible is scheduled to expire.
What's Actually Expiring
During the COVID-19 public health emergency, the DEA temporarily waived the Ryan Haight Online Pharmacy Consumer Protection Act requirement that prescribers conduct an in-person examination before issuing a controlled substance prescription via telehealth. Testosterone is a Schedule III controlled substance. Without this waiver, federal law requires that your prescriber physically examine you before writing that first testosterone prescription over a video call.
This waiver has been extended multiple times since the original public health emergency declaration ended. The current extension expires December 31, 2026. After that date, the waiver either gets extended again, replaced by a permanent rule, or lapses — and the implications for each scenario are very different.
The Three Possible Outcomes
Scenario 1: Another Extension
This is what's happened every previous time the deadline approached. Political pressure from the telehealth industry, patient advocacy groups, and prescribers has produced successive extensions. Another extension would maintain the status quo — your existing telehealth TRT arrangement continues unchanged.
Likelihood: Moderate. Each extension becomes politically harder to justify as COVID recedes further into history. The DEA has signaled it wants a permanent framework, not perpetual temporary measures.
Scenario 2: The Special Registration Pathway
The DEA proposed a "Special Registration" rule that would allow certain qualified telehealth practitioners to continue prescribing controlled substances without an initial in-person visit. The proposed rule includes requirements for state licensing, DEA registration, recordkeeping, and patient verification that go beyond current temporary flexibility but still allow audio-video telemedicine prescribing.
If finalized, this would create a permanent legal framework for telehealth TRT that replaces the temporary waiver. Your telehealth provider would need to obtain Special Registration — an administrative burden on the platform, not on you — but the patient experience would remain largely unchanged.
Likelihood: Moderate to high. The DEA has invested significant rulemaking effort. But the final rule hasn't been published as of mid-2026, and the timeline for implementation after publication is uncertain.
Scenario 3: The Waiver Lapses
If the waiver expires without extension or replacement, the Ryan Haight Act's in-person examination requirement snaps back into effect for new prescribing relationships. What this means in practice:
- New patients: Could not start TRT via telehealth without first completing an in-person examination with the prescribing clinician or a DEA-registered practitioner.
- Existing patients: The legal status is less clear. Some interpretations suggest that established prescriber-patient relationships (where a controlled substance has already been prescribed under the waiver) could continue under existing state telemedicine laws. Other interpretations suggest that refills after the waiver expires would also require an in-person encounter.
Likelihood: Low but non-zero. The political and practical consequences of abruptly cutting off telehealth access to controlled substances for millions of patients make this the least likely scenario — but regulatory processes don't always produce rational outcomes.
What the Deadline Means for You Specifically
If You're Currently on Telehealth TRT
- Your immediate prescriptions are safe. Medications already prescribed and in your possession aren't affected by regulatory changes.
- Refills after December 31 are uncertain. The ability to continue receiving refills via telehealth depends on which scenario plays out.
- Establish your relationship now. Being an existing patient with an established prescriber relationship is always more favorable than being a new patient under stricter rules.
- Ask your platform. Reputable telehealth TRT providers should have a contingency plan. If they can't articulate one, that's concerning.
If You're Considering Starting TRT
- Starting before the deadline is strategically advantageous. An established prescriber-patient relationship under the current rules provides better standing regardless of what happens next.
- Don't rush into TRT just because of a deadline. The medical decision to start testosterone should be based on clinical need, not regulatory timing. Get proper labs, get properly evaluated, and start if it's medically indicated.
- Consider platforms with physical presence. Providers that have both telehealth and in-person options (or partnerships with local clinicians) are better positioned for any regulatory outcome.
What Your Platform Should Be Doing
Responsible telehealth TRT providers are preparing for the deadline through several mechanisms:
- Special Registration preparation: Platforms that anticipate the DEA rule are already preparing their clinicians for the new registration requirements.
- Local clinical partnerships: Some platforms are establishing relationships with brick-and-mortar clinics that can provide the in-person examination if required, while the platform continues managing the ongoing telehealth relationship.
- Patient communication: Proactive platforms are communicating with patients about the deadline and their contingency plans. Silence on this topic is a red flag.
The Bottom Line
Prepare, Don't Panic
The December 31, 2026 deadline is real and consequential — but catastrophic disruption to existing TRT access is unlikely. The most probable outcome is either another extension or finalization of the Special Registration pathway. The smart move: ensure your current telehealth relationship is well-established, ask your provider about their contingency plan, and have a backup local prescriber identified. Preparation eliminates the need for panic.